Skip to main content
Premium Trial:

Request an Annual Quote

Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test

NEW YORK – Cota, PreciseDx, and Baptist Health South Florida on Wednesday said they are collaborating to validate PreciseDx's PreciseBreast test to predict the likelihood of invasive breast cancer recurrence.

Cota, which is based in Irvine, California, and Baptist Health will evaluate the artificial intelligence-powered test by comparing PreciseBreast results with traditional pathology reviews and results from a 21-gene assay using real-world data from Cota. If they are able to successfully validate the assay's performance, Baptist Health will offer the test to patients with invasive breast cancer.

PreciseBreast examines millions of data points from standard pathology slide images to generate via AI a recurrence risk score.

"By combining state-of-the-art technology with real-world evidence, we are working to not only enhance our diagnostic precision but also improve accessibility that may ultimately empower both patients and physicians with timely, actionable insights," Miami Cancer Institute of Baptist Health South Florida CSO Manmeet Ahluwalia said in a statement.

Cota curates and organizes real-world oncology data for researchers, drugmakers, and regulators. Cota recently partnered with Caris Life Sciences to apply its genomic, transcriptomic, proteomic, and imaging data from more than 2 million cancer patients to support drug development. It inked a similar partnership in 2023 with Genomic Testing Cooperative to integrate real-world clinical and outcomes data with tissue- and blood-based DNA and RNA profiling data to personalize cancer treatment.